ProfileJobs

Caladrius

Healthbiotechclinical researchpharma

Caladrius Biosciences, Inc. (formerly NeoStem) is a cell therapy development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s subsidiary, PCT, is a development and manufacturing partner exclusively focused on the cell therapy industry. PCT provides a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage, and distribution, as well as expert consulting and regulatory support.

Revenue(Q1, 2017)
$7.9 M
Market capitalization(2017-06-22)
$38.3 M
Company Growth (employees)
Type
Public
HQ
Bernards, US
Founded
2006
Size (employees)
209 (est)
Website
caladrius.com
Caladrius was founded in 2006 and is headquartered in Bernards, US

Caladrius Office Locations

Caladrius has offices in Bernards and New York
Bernards, US (HQ)
4th Floor 106 Allen Rd
New York, US
350 420 Lexington Ave

Caladrius Data and Metrics

Caladrius Financial Metrics

Caladrius's revenue was reported to be $7.9 m in Q1, 2017
USD

Revenue (Q1, 2017)

7.9 m

Gross profit (Q1, 2017)

(119.6 k)

Gross profit margin (Q1, 2017), %

(2%)

Net income (Q1, 2017)

(9.8 m)

EBIT (Q1, 2017)

(9.5 m)

Market capitalization (22-Jun-2017)

38.3 m

Closing share price (22-Jun-2017)

4.2

Cash (31-Mar-2017)

12 m
Caladrius's current market capitalization is $38.3 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

14.7 m17.9 m22.5 m35.3 m

Revenue growth, %

22%25%57%

Cost of goods sold

12.9 m15.7 m20.2 m31.1 m

Gross profit

1.7 m2.3 m2.3 m4.1 m

Gross profit Margin, %

12%13%10%12%

EBIT

(36.8 m)(57.7 m)(113.8 m)(31.3 m)

EBIT margin, %

(251%)(322%)(506%)(89%)

Net Income

(39.5 m)(55.5 m)(81 m)(33.3 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

4.5 m4.1 m3.2 m5.9 m5.9 m7.5 m8.3 m9.3 m7.9 m

Cost of goods sold

3.7 m4 m3.4 m5.8 m4.8 m6.2 m7.1 m8.6 m8 m

Gross profit

811.6 k105.4 k(196.3 k)68.2 k1.1 m1.3 m1.2 m706.3 k(119.6 k)

Gross profit Margin, %

18%3%(6%)1%18%17%15%8%(2%)

R&D expense

5.8 m8.5 m6.8 m7.6 m6.3 m5.9 m4 m2.6 m3.5 m

Operating expense total

5.8 m8.5 m6.8 m7.6 m6.3 m5.9 m4 m2.6 m3.5 m

EBIT

(12.4 m)(16.3 m)(18.1 m)(25.7 m)(10.4 m)(11.1 m)(7.5 m)(6.9 m)(9.5 m)

EBIT margin, %

(277%)(395%)(570%)(438%)(176%)(148%)(90%)(74%)(120%)

Interest expense

105.9 k183.5 k551 k547.3 k553 k926.8 k359.7 k384.9 k167.7 k

Income tax expense

47.4 k47.4 k46.6 k(3.7 m)46.6 k53.4 k47 k47 k49.5 k

Net Income

(26.6 m)(43.8 m)(19.2 m)(36.4 m)(47.8 m)(12 m)(19.9 m)(27.2 m)(9.8 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

46.1 m19.2 m20.3 m14.7 m

Inventories

1.3 m

Current Assets

50.8 m36.3 m29.3 m24.6 m

PP&E

12.8 m16 m17.1 m17.1 m

Goodwill

11.1 m25.2 m7 m7 m

Total Assets

89.8 m126.3 m57.2 m51.8 m

Accounts Payable

3.4 m5.7 m4.1 m4.4 m

Total Debt

3.4 m2.4 m584.4 k

Current Liabilities

9.8 m16.2 m21 m19.5 m

Total Liabilities

28.4 m

Additional Paid-in Capital

299.6 m350.4 m396.5 m410.4 m

Retained Earnings

(236.4 m)(291.2 m)(372.1 m)(404.8 m)

Total Equity

62 m58.1 m23.3 m4.1 m

Debt to Equity Ratio

0.1 x0.1 x0.1 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

1.4 x2.2 x2.5 x12.7 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

32.9 m32.1 m19.1 m36.2 m24 m25.4 m17.7 m18.6 m12 m

Inventories

2 m2.1 m

Current Assets

40.9 m41.4 m29 m47.5 m38.5 m35.6 m29.3 m30 m21.9 m

PP&E

15.6 m15.7 m15.9 m16.8 m17.1 m16.9 m17 m17.1 m16.8 m

Goodwill

26.1 m25.2 m25.2 m25.2 m25.2 m7 m7 m7 m7 m

Total Assets

133.4 m131.3 m118.8 m128.6 m119.7 m63.2 m56.7 m57.3 m48.5 m

Accounts Payable

5.5 m4.4 m2.9 m2.3 m2.5 m4 m2.9 m3.2 m3.6 m

Current Liabilities

11.9 m11.9 m17.5 m16.3 m19.7 m18.5 m22.4 m18.6 m23.2 m

Additional Paid-in Capital

341.4 m343.3 m361.5 m394.6 m395 m398.4 m398.7 m410.3 m414.1 m

Retained Earnings

(262.7 m)(279.6 m)(310.4 m)(327.6 m)(338.9 m)(384.1 m)(391.9 m)(398.8 m)(414.1 m)

Total Equity

77.3 m62.1 m50 m66 m55 m13.2 m5.6 m10 m(2 m)

Financial Leverage

1.7 x2.1 x2.4 x2 x2.2 x4.8 x10.1 x5.7 x-24.6 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(39.5 m)(55.5 m)(81 m)(33.3 m)

Depreciation and Amortization

1.6 m2.2 m2.7 m2.7 m

Accounts Receivable

(573 k)(1.2 m)545.2 k(325.6 k)

Inventories

(758.8 k)(2.8 m)

Cash From Operating Activities

(27.1 m)(46.9 m)(39.3 m)(23.7 m)

Purchases of PP&E

(2.7 m)3.7 m3.2 m(2.8 m)

Cash From Investing Activities

(2.7 m)(10.7 m)3.8 m(2.8 m)

Long-term Borrowings

(9.3 m)

Cash From Financing Activities

62.2 m30.7 m36.6 m20.9 m

Interest Paid

274.1 k232.5 k1.5 m1.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(26.6 m)(43.8 m)(19.2 m)(36.4 m)(47.8 m)(12 m)(19.9 m)(27.2 m)(9.8 m)

Depreciation and Amortization

987.7 k1.6 m604.4 k1.3 m1.9 m737.2 k1.4 m2.1 m655.3 k

Accounts Receivable

(602.1 k)(177.2 k)1.1 m1.8 m815.2 k(46.7 k)(326.4 k)(1.7 m)(277 k)

Inventories

(762.8 k)(872.1 k)

Cash From Operating Activities

(22.5 m)(36 m)(14.2 m)(21.8 m)(30.5 m)(8 m)(14.6 m)(20.3 m)(10.1 m)

Purchases of PP&E

(2.4 m)(2.9 m)(344.5 k)(1.8 m)(2.6 m)(1 m)(1.7 m)(2.3 m)(171.3 k)

Cash From Investing Activities

(3.3 m)(3.5 m)6.7 m2.2 m(921.2 k)(1 m)(1.7 m)(2.3 m)(171.3 k)

Long-term Borrowings

(6.3 m)(6.3 m)(9.3 m)(757 k)

Cash From Financing Activities

12.5 m25.5 m7.5 m36.6 m36.3 m14.2 m13.7 m20.9 m7.6 m

Interest Paid

196.2 k359.3 k372.6 k744.8 k1.1 m973.7 k1.2 m1.7 m130.2 k
USDY, 2017

Revenue/Employee

37.2 k

Financial Leverage

-24.6 x

Market Position of Caladrius

Competitors

Sophiris
Health - Public
Rodeo Therapeutics
Health - Private
BlackThorn Therapeutics
Health - Private
Acceleron Pharma
Health - Public
Compare competitors

Traffic Overview of Caladrius

Caladrius Online and Social Media Presence

Caladrius Company Life and Culture

You may also be interested in